<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01713946</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001M2304</org_study_id>
    <secondary_id>2011-000860-90</secondary_id>
    <nct_id>NCT01713946</nct_id>
  </id_info>
  <brief_title>A Placebo-controlled Study of Efficacy &amp; Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) &amp; Refractory Partial-onset Seizures</brief_title>
  <acronym>EXIST-3</acronym>
  <official_title>A Three-arm, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Two Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) Who Have Refractory Partial-onset Seizures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of two trough-ranges of everolimus given as
      adjunctive therapy in patients with tuberous sclerosis complex (TSC) who have refractory
      partial-onset seizures.

      The study consists of 4 phases for each patient [Baseline phase: From Screening Week -8 (V1)
      to randomization visit at Week 0 (V2)], Core phase, from randomization at Week 0 (V2) to Week
      18 (V11)], Extension phase from Week 18 (V11) until 48 weeks after the last patient has
      completed the core phase, and Post Extension Phase.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 29, 2013</start_date>
  <completion_date type="Actual">October 25, 2017</completion_date>
  <primary_completion_date type="Actual">October 2, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>European Medicine Agency (EMA): Response rate</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Response means at least a 50% reduction from baseline in partial-onset seizure frequency</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Food &amp; Drug Administration (FDA): Percentage reduction in partial onset seizure frequency</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Percentage reduction from baseline in partial onset seizure frequency during maintenance period of the core phase.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seizure free rate</measure>
    <time_frame>Baseline, Week 6, Week 18</time_frame>
    <description>Seizure free means a 100% reduction in partial onset-seizure frequency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with at least a 25% reduction in partial onset seizure frequency</measure>
    <time_frame>Baseline, Week 6, Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Categorical variable of six levels of reduction from baseline in partial-onset seizure frequency</measure>
    <time_frame>Baseline, Week 6 to 18 (during maintenance of core phase)</time_frame>
    <description>Six levels of reduction: (≤ -25% (exacerbation); &gt; -25% to &lt; 25% (no change); ≥ 25% to &lt; 50%; ≥ 50% to &lt; 75%; ≥ 75% to &lt; 100%; 100% (seizure-freedom)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of seizure free days</measure>
    <time_frame>Week 6, Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment duration</measure>
    <time_frame>Week 0 (randomization), Week 18</time_frame>
    <description>Time from randomization until treatment discontinuation in the Core phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Quality of Life global scores</measure>
    <time_frame>Baseline, Week 18, and End of Treatment (time when patient completes or leaves study. Range from 74 to 142 weeks)</time_frame>
    <description>Taken from the 3 age-specific questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-test scores for neurocognitive, neurodevelopmental, and neurobehavioral tests</measure>
    <time_frame>Baseline, 18 weeks (End of Core), Every 6 months during Extension, End of Treatment Extension (time when patient completes or leaves study. Range from 74 to 142 weeks)</time_frame>
    <description>Changes in the Vineland Adaptive Behavior Scales-II and the Wechsler Non-Verbal Scale of Ability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage reduction in seizure frequency/frequency of selected adverse events</measure>
    <time_frame>Baseline, end of study (if patient completes range from 74 to 142 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-dose concentrations of anti-epileptic drugs (AEDs) alone and post-baseline (AEDs plus everolimus)</measure>
    <time_frame>Baseline, Week 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>50% response rate from Baseline by time interval over the extension phase</measure>
    <time_frame>Week 18 (start of Extension), End of Treatment Extension (time when patient completes or leaves study. Range from 74 to 142 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seizure free days in partial onsent seizure by time interval over the extension phase</measure>
    <time_frame>Week 18 (Start of Extension), End of Treatment Extension (time when patient completes or leaves study. Range from 74 to 142 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>Baseline, End of Treatment Extension (time when patient completes or leaves study. Range from 74 to 142 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of abnormal laboratory values</measure>
    <time_frame>Baseline, End of Treatment Extension (time when patient completes or leaves study. Range from 74 to 142 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Columbia Suicide Severity Rating Scale (C-SSRS) outcomes</measure>
    <time_frame>Week 8 (screening), End of Treatment Extension (time when patient completes or leaves study. Range from 74 to 142 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of serious adverve events (SAEs) referring to a positive suicidal evaluation</measure>
    <time_frame>Week 8 (Screening), End of Treatment Extension (time when patient completes or leaves study. Range from 74 to 142 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">370</enrollment>
  <condition>Tuberous Sclerosis Complex-associated Refractory Seizures</condition>
  <arm_group>
    <arm_group_label>Everolimus low trough</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>everolimus titrated to 3 to 7 ng/mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Everolimus high trough</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>everolimus titrated to 9 to 15 ng/mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RAD001</intervention_name>
    <arm_group_label>Everolimus low trough</arm_group_label>
    <arm_group_label>Everolimus high trough</arm_group_label>
    <other_name>Afinitor, Votubia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Male or female between the ages of 2 and 65 years (except in Europe where minimum
             age will be 1).

             2. Clinically definite diagnosis of TSC per modified Gomez criteria 3. Diagnosis of
             partial-onset epilepsy according to the classification of the International League
             Against Epilepsy (1989) and revised in 2009.

             4. Uncontrolled partial-onset seizures; must meet the following:

               1. At least 16 reported quantifiable partial-onset seizures over the Baseline period
                  with no continuous 21-day seizure-free period between Visit 1 (Screening Visit)
                  and Visit 2 (Randomization visit), as per data captured in daily seizure diaries.

               2. Prior history of failure to control partial-onset seizures despite having been
                  treated with two or more sequential regimens of single or combined antiepileptic
                  drugs.

               3. Prior or concurrent use of vagal nerve stimulator (VNS) is allowed. If the
                  patient is using VNS, device stimulator parameters must remain constant
                  throughout the study.

               4. Prior epilepsy surgery is allowed if performed at least 12 months before study
                  entry.

                  5. Must be receiving one, two, or three AEDs at a stable dose for at least 4
                  weeks at the start of the 8-week prospective Baseline phase, remain on the same
                  regimen throughout the Baseline phase, and intend to continue the same regimen
                  throughout the 18-week double blind Core phase (rescue medications are
                  permitted).

                  6. If female of child bearing potential, documentation of negative pregnancy test
                  at time of informed consent and must use highly effective contraception during
                  the study and for 8 weeks after stopping treatment 7. Sexually active males must
                  use a condom during intercourse while taking study drug, and for 8 weeks after
                  stopping study treatment 8. Hepatic, renal and blood laboratory values within the
                  following range at screening :

               1. AST and ALT levels &lt; 2.5 x ULN

               2. serum bilirubin &lt;1.5 × ULN (this limit does not apply to patients with an
                  elevated indirect bilirubin, if they have Gilbert's Syndrome),

               3. serum creatinine &lt; 1.5 x ULN

               4. hemoglobin ≥ 9 g/dL

               5. platelets ≥ 80,000/mm3

               6. absolute neutrophil count ≥ 1,000/mm3 9. Written informed consent. Subjects or
                  their legal guardians must have the ability to comprehend the informed consent
                  form and be willing to provide informed consent.

                  10. Patient or caregiver must be able to reliably record seizures and keep a
                  daily diary and recall adverse events.

                  Exclusion Criteria:

          -  1. Patients with seizures secondary to metabolic, toxic, infectious or psychogenic
             disorder or drug abuse or current seizures related to an acute medical illness.

             2. Presence of only non-motor partial seizures (NOT APPLICABLE per Amendment 2) 3.
             Patients with TSC who have SEGA in need of immediate surgical intervention. 4.
             Patients under 2 years of age with untreated infantile spasms. 5. Within 52 weeks
             prior to study entry, an episode of status epilepticus as defined in the protocol.

             6. Patients with history of seizure clusters (where individual seizures cannot be
             accurately counted according to the judgment of the investigator) occurring within 26
             weeks prior to study entry.

             7. Patients who require rescue medication during the baseline phase for more than 6
             days 8. Patients with non-TSC related progressive encephalopathy. 9. Patients who
             weigh less than 12 kg. 10. Patients with coexisting malignancies within the 3 years
             prior to randomization, except for adequately treated carcinoma of the cervix or basal
             or squamous cell carcinomas of the skin.

             11. Patients with any severe and/or uncontrolled medical conditions at randomization
             such as:

               1. Symptomatic congestive heart failure of New York Heart Association Class III or
                  IV, history of left ventricular ejection fraction (LVEF) &lt; 50%, QTc interval
                  &gt;460ms, congenital QT syndrome, unstable angina pectoris, myocardial infarction
                  within 6 months of study entry, serious uncontrolled cardiac arrhythmia or any
                  other clinically significant cardiac disease.

               2. Significant symptomatic deterioration of lung function

               3. Impairment of gastrointestinal function or gastrointestinal disease that may
                  significantly alter the absorption of everolimus (e.g., ulcerative disease,
                  malabsorption syndrome or small bowel resection).

               4. liver disease such as cirrhosis, decompensated liver disease, and chronic
                  hepatitis

               5. Uncontrolled diabetes as defined by fasting serum glucose &gt; 1.5 × ULN.

               6. Active skin, mucosa, ocular or GI disorders of Grade &gt; 1.

               7. Active (acute or chronic) or uncontrolled severe infections.

               8. A known history of HIV seropositivity or other active viral infections. 12.
                  Patients with an active, bleeding diathesis. 13. Patient with uncontrolled
                  hyperlipidemia: fasting serum cholesterol &gt; 300 mg/dL OR &gt;7.75 mmol/L AND fasting
                  triglycerides &gt; 2.5 x ULN.

                  14. Patients who have had a major surgery or significant traumatic injury within
                  4 weeks of study entry.

                  15. Patients with a prior history of organ transplant. 16. Patients receiving
                  more than 3 antiepileptic drugs at any time in the baseline phase or at
                  randomization or who change the dose of the AEDs during 4 weeks before screening
                  or during the baseline period.

                  17. Patients being treated with felbamate, unless treatment has been continuous
                  for ≥ 1 year.

                  18. Patients currently receiving anticancer therapies or who have received
                  anticancer therapies within 4 weeks of study entry (including chemotherapy,
                  radiation therapy, antibody based therapy, etc.).

                  19. Prior treatment with any investigational drug within the preceding 4 weeks
                  prior to study entry.

                  20. Patients receiving chronic, systemic treatment with corticosteroids or
                  another immunosuppressive agent at study entry. Topical or inhaled
                  corticosteroids are allowed.

                  21. Patients who have received prior treatment with a systemic mTOR inhibitor
                  (sirolimus, temsirolimus, everolimus) within 24 months of study entry. Patients
                  who have received prior treatment with a topical mTOR inhibitor (sirolimus,
                  temsirolimus, everolimus) within 4 weeks of study entry.

                  22. Patients with a known hypersensitivity to everolimus or other
                  rapamycin-analogues (sirolimus, temsirolimus) or to its excipients.

                  23. Patients with a history of non-compliance to medical regimens or who are
                  considered potentially unreliable or will not be able to complete the entire
                  study 24. Pregnant or nursing (lactating) women, where pregnancy is defined as
                  the state of a female after conception and until the termination of gestation,
                  confirmed by a positive hCG laboratory test.

                  25. Patients with a Score of 4 or 5 on the Suicidal Ideation item within 2 years
                  of Screening, or any &quot;yes&quot; on the Suicidal Behavior item of the Columbia-Suicide
                  Severity Rating Scale at Screening or Baseline , who upon follow up with a
                  healthcare professional are found to be severely depressed or suicidal.

                  26. Maintenance of a diet consisting of &lt;40 g of carbohydrate per day within 3
                  months of screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham SC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TGen/APNNA</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at Los Angeles SC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Oakland SC</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County SC</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868-3874</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital SC</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado SC</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connecticut Childrens Medical Center SC</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center SC - 2</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kennedy Krieger Institute SC</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston SC</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Epilepsy Group - PA SC</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102-2383</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine SC-2</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morristown Memorial Hospital SC-2</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University Medical Center SC-3</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center SC</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University SC - 3</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia SC</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4399</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LeBonheur Childrens Medical Group SC</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Scottish Rite Hospital for Children Texas Scottish</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital SC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas Medical School-Houston SC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1428AQK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <zip>X5000JJS</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6840</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cali</city>
        <state>Valle Del Cauca</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Medellín</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aarhus</city>
        <zip>8000 C</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amiens Cedex 1</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bron Cedex</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Strasbourg Cedex</city>
        <zip>F-67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bielefeld</city>
        <zip>33617</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kehl-Kork</city>
        <zip>77694</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ioannina</city>
        <state>GR</state>
        <zip>455 00</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <zip>15236</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nyiregyhaza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dublin</city>
        <zip>12</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Catania</city>
        <state>CT</state>
        <zip>95100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Siena</city>
        <state>SI</state>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Okayama-city</city>
        <state>Okayama</state>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Izumi-city</city>
        <state>Osaka</state>
        <zip>594-1101</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka-city</city>
        <state>Osaka</state>
        <zip>534-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Suita-city</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shizuoka-city</city>
        <state>Shizuoka</state>
        <zip>420-8688</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Setagaya-ku</city>
        <state>Tokyo</state>
        <zip>157-8535</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heeze</city>
        <zip>5591 VE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Utrecht</city>
        <zip>3584CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Samara</city>
        <state>Samara Region</state>
        <zip>443095</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Voronezh</city>
        <state>Voronezh Region</state>
        <zip>394024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>127412</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucía</state>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Sebastian</city>
        <state>Pais Vasco</state>
        <zip>20080</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tainan</city>
        <state>Taiwan ROC</state>
        <zip>70421</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ankara</city>
        <zip>06500</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2WB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buckinghamshire</city>
        <zip>SL9 0RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liverpool</city>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>York</city>
        <zip>YO31 7EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Sweden</country>
  </removed_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2012</study_first_submitted>
  <study_first_submitted_qc>October 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2012</study_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TSC seizures,</keyword>
  <keyword>TSC epilepsy,</keyword>
  <keyword>mTOR inhibitor,</keyword>
  <keyword>RAD001,</keyword>
  <keyword>Everolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Tuberous Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <pending_results>
    <submitted>April 25, 2018</submitted>
    <returned>May 25, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

